Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Prior treatment

• History of intraocular surgery within 1 month before screening in the study eye;

Other illness

• Any condition in the investigator's opinion that could limit VA improvement in the study eye.
• History of retinal detachment in the study eye at any time;
• History of idiopathic or autoimmune uveitis in either eye;
• History of vitrectomy surgery in the study eye;
• History of ocular or systemic gene therapy;
• Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months.

Other

• CNV or macular edema in the study eye secondary to any causes other than AMD
• Subfoveal atrophy in the study eye, as determined by CRC;
• Advanced glaucoma in the study eye;

• Willing and able to provide written, signed informed consent for this study;
• Age ≥50 and ≤80 years old;
• Active CNV secondary to nAMD in the study eye confirmed by FFA or OCT;
• The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening;
• Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
• No anti-VEGF therapy in study eye within 28 days before screening;
• Must be pseudophakic in the study eye.